Clinical Trial: A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07677514) titled 'A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease' on June 11.

Brief Summary: This study employs a multicenter, randomized, double-blind, placebo-controlled, parallel-group, continuous treatment design to evaluate the efficacy, safety, PPK characteristics, and PD effects of H021 Enteric-coated Tablets during both the induction and maintenance treatment periods in patients with moderately to severely active CD.

This study consists of an up to 4-week screening period, a 12-week double-blind induction treatment period, a 40-week double-blind maintenance treatment period or open-label exte...